All data are based on the daily closing price as of December 24, 2024
t

Takara Bio

4974.TSE
6.39 USD
0.06
+0.95%

Overview

Last close
6.39 usd
Market cap
769.28M usd
52 week high
12.45 usd
52 week low
6.19 usd
Target price
9.34 usd

Valuation

P/E
132.4037
Forward P/E
N/A
Price/Sales
2.7194
Price/Book Value
1.0303
Enterprise Value
540.66M usd
EV/Revenue
1.9228
EV/EBITDA
13.029

Key financials

Revenue TTM
281.19M usd
Gross Profit TTM
313.45M usd
EBITDA TTM
43.38M usd
Earnings per Share
0.05 usd
Dividend
0.11 usd
Total assets
757.21M usd
Net debt
-221.40M usd

About

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
  • Symbol
    4974.TSE
  • Exchange
    TSE
  • Isin
    JP3460200003
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Koichi Nakao
  • Headquarter
    Kusatsu
  • Web site
    https://www.takara-bio.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top